

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IL05/000084

International filing date: 23 January 2005 (23.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/538,635
Filing date: 22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 01 March 2005 (01.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

17 FEB 2005

PA 1277645

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


January 31, 2005


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/538,635

FILING DATE: January 22, 2004

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**




M. K. HAWKINS
Certifying Officer

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EL988370011US

INVENTOR(S)

Given Name (first and middle [if any])

Family Name or Surname

Residence
(City and either State or Foreign Country)

Benjamin

Sredni

Shachal 3
Kfar Saba
IsraelAdditional inventors are being named on the 2 separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max)**

TREATMENT OF WARTS WITH TELLURIUM COMPOUNDS

22264 U.S. PTO
60/538635

Direct all correspondence to:

CORRESPONDENCE ADDRESS

Customer Number

Place Customer Number
Bar Code Label here

OR

Type Customer Number here

Firm or
Individual Name

Hedman & Costigan, P.C.

Address

James V. Costigan

Address

1185 Avenue of the Americas

City

New York

State

New York

ZIP

10036-2646

Country

USA

Telephone

212-302-8989

Fax

212-302-8998

ENCLOSED APPLICATION PARTS (check all that apply)

Specification Number of Pages

19



CD(s), Number



Drawing(s) Number of Sheets

3



Other (specify)



Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

Applicant claims small entity status. See 37 CFR 1.27.



A check or money order is enclosed to cover the filing fees



The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:

08-1540



Payment by credit card. Form PTO-2038 is attached.

FILING FEE
AMOUNT (\$)

\$80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No.



Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME James V. Costigan

TELEPHONE (212) 302-8989

Date

01/22/2004

REGISTRATION NO.
(if appropriate)

25,669

Docket Number:

116-043

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PROVISIONAL APPLICATION COVER SHEET

Additional Page

PTO/SB/16 (02-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

116-043

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Michael	Albeck	8 Harel Street Ramat Gan Israel

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

116-043

UNITED STATES PATENT APPLICATION OF

5

Benjamin Sredni
Michael Albeck

10

for

15

TREATMENT OF WARTS WITH TELLURIUM COMPOUNDS

20

BACKGROUND OF THE INVENTION:

5 Field of the Invention

This invention relates to the treatment of various warts.

10 Description of the Related Art

In U.S. 4,752,614, which is incorporated by reference, the use of certain tellurium compounds as anti-viral agents in plants or animals is disclosed. The virus that is exemplified is West Nile Virus. There is no known disclosure in the prior art of the use of tellurium compounds for the treatment of viral infections in humans.

Verrucae or warts as verrucae are commonly known, are generally defined as a contagious, epithelial tumor caused by at least 35 different types of human papilloma virus (HPV). Viral warts have been diagnosed in patients without regard to age or sex. The incidence of warts is most common in older children and is least common in persons of advanced age. Warts most often occur on the skin but may occur at any location in the body and may spread by auto-innoculation. In some cases complete regression occurs after several months with or without treatment with recurrence at the same or at different locations. The types of warts include common (verruca vulgaris, plantar, palmar and periungal); flat; genital (Condylomata acuminata); butcher's; malignant epidermodysplasia verruciformis; mepidermodysplasia verruciformis; cutaneous warts in immunosuppressed patients; laryngeal papillomas; and oral papilloma. Each of these conditions has been linked to specific types or groups of papilloma viruses. Various topical and/or surgical techniques have been used for treating warts but no method

of treatment has been consistently effective. Surgical treatments have resulted in discomfort, prolonged healing and the formation of scars and/or keloids to a greater or lesser extent. Accordingly, a need exists for an improved
5 method of treating warts.

SUMMARY OF THE INVENTION:

The subject invention pertains to a method for
10 treatment of warts which comprises the administration of an effective amount of a tellurium compound to one who is afflicted with warts. The method of treatment includes the topical and systemic administration of a tellurium compound

Accordingly, it is a primary object of the invention
15 to provide a method for the treatment of warts which comprises the topical application of an effective amount of a tellurium compound to a wart.

It is also an object of this invention to provide a method for the treatment of warts which comprises the
20 systemic administration of an effective amount of a tellurium compound to an afflicted patient.

It is also an object of this invention to provide a method for the treatment of warts which avoids the scarring
25 and prolonged healing that accompanies surgical removal of warts.

These and other objects of the invention will become apparent from a review of the specification.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a photograph prior to treatment of a patient afflicted with condyloma warts.

Fig. 2 is a photograph after about two weeks of treatment as described in Example 1.

Fig. 3 is a photograph after about four weeks of treatment as described in Example 1.

Fig. 4 is a photograph after about six weeks of treatment as described in Example 1.

Fig. 5 is a photograph after about eight weeks of treatment as described in Example 1.

Fig. 6 is a photograph of the treatment of a verucca wart as described in Example 2 at the beginning of treatment.

Fig. 7 is a photograph after about two weeks of treatment as described in Example 2.

Fig. 8 is a photograph after about four weeks of treatment as described in Example 2.

Fig. 9 is a photograph of the treatment of verucca warts as described in Example 3 at the beginning of treatment.

Fig. 10 is a photograph after about two weeks of treatment as described in Example 3.

Fig. 10 is a photograph after about two weeks of treatment as described in Example 3.

Fig. 11 is a photograph after about four weeks of treatment as described in Example 3.

5


DETAILED DESCRIPTION OF THE INVENTION:

The tellurium compounds for use in the invention include those of the formula:

15


20

25



30

35



or

40

TeO_2 or complexes of TeO_2
(C)

or

5

PhTeCl₃

(D)

or

5

TeX₄, when X is Cl, Br or F

or the following complex: TeO₂.HOCH₂CH₂OH.NH₄Cl;

10 or


(C₆H₅)₄P⁺(TeCl₃(O₂C₂H₄)) -

(E)


wherein t is 1 or 0; u is 1 or 0; v is 1 or 0; R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉ are the same or different and are independently selected from the group consisting of hydrogen, hydroxyalkyl of 1 to 5 carbons, hydroxy, alkyl or from 1 to 5 carbon atoms, halogen, haloalkyl of 1 to 5 carbon atoms, carboxy, alkylcarbonylalkyl of 2 to 10 carbons, alkanoyloxy of 1 to 5 carbon atoms, carboxyalkyl of 1 to 5 carbons atoms, acyl, amido, cyano, amidoalkyl of 1 to 5 carbons, N-monoalkylamidoalkyl of 2 to 10 carbons, N,N-dialkylamidoalkyl of 4 to 10 carbons, cyanoalkyl of 1 to 5 carbons alkoxy of 1 to 5 carbon atoms, alkoxyalkyl of 2 to 10 carbon atoms and -COR₁₀ wherein R₁₀ is alkyl of 1 to 5 carbons; and X is halogen; while the ammonium salt is illustrated, it is understood that other pharmaceutically acceptable salts such as K⁺ are within the scope of the invention. The compounds with the five membered rings are preferred.

As used herein and in the appended claims, the term alkyl of 1 to 5 carbon atoms includes straight and branched chain alkyl groups such as methyl; ethyl; n-propyl; n-butyl, and the like; the term hydroxyalkyl of 1 to 5 carbon atoms includes hydroxymethyl; hydroxyethyl; hydroxy-n-butyl; the term haloalkyl of 1 to 5 carbon atoms includes chloromethyl; 2-iodoethyl; 4-bromo-n-butyl; iodoethyl; 4-bromo-n-pentyl and the like; the term alkanoyloxy of 1 to 5 carbon atoms

includes acetyl, propionyl, butanoyl and the like; the term carboxyalkyl includes carboxymethyl, carboxyethyl, ethylenecarboxy and the like; the term alkylcarbonylalkyl includes methanoylmethyl, ethanoylethyl and the like; the term amidoalkyl includes $-\text{CH}_2\text{CONH}_2$; $-\text{CH}_2\text{CH}_2\text{CONH}_2$; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CONH}_2$ and the like; the term cyanoalkyl includes $-\text{CH}_2\text{CN}$; $-\text{CH}_2\text{CH}_2\text{CN}$; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CN}$ and the like; the alkoxy, of 1 to 5 carbon atoms includes methoxy, ethoxy, n-propoxy, n-pentoxo and the like; the terms halo and halogen are used to signify chloro, bromo, iodo and fluoro; the term acyl includes R_{16}CO wherein R_{16} is H or alkyl of 1 to 5 carbons such as methanoyl, ethanoyl and the like; the term aryl includes phenyl, alkylphenyl and naphthyl; the term N-monoalkylamidoalkyl includes $-\text{CH}_2\text{CH}_2\text{CONHCH}_3$, $-\text{CH}_2\text{CONHCH}_2\text{CH}_3$; the term N,N-dialkylamidoalkyl includes $-\text{CH}_2\text{CON}(\text{CH}_3)_2$; $\text{CH}_2\text{CH}_2\text{CON}(\text{CH}_2\text{-CH}_3)_2$. The tellurium based compounds that are preferred include those of the formula:




and




wherein X is halogen. The preferred halogen species is

chloro.

Other compounds which are based on tellurium and may be used in the practice of the invention include PhTeCl_3 , TeO_2 and TeX_4 (C_6H_5)₄ P^+ ($\text{TeCl}_3(\text{O}_2\text{C}_2\text{H}_4)$)⁻ (Z. Naturforsch, 36, 307-312 (1981)). Compounds of the following structure are also included:




Other compounds useful for the practice of invention include:



wherein R_{11} , R_{12} , R_{13} and R_{14} are independently selected from the group consisting of hydrogen, hydroxy-alkyl of 1-5 carbons atoms, hydroxy and alkyl of 1-5 carbons atoms.

Useful dihydroxy compounds for use in the preparation of compounds of structure A or B, include those of formula I wherein R, R_1 , R_4 and R_5 are as shown in the Table:

TABLE



(I)

R	R_1	R_4	R_5
H	H	H	H

5	H	Cl	H	H
	H	OCH ₃	H	H
	H	COOCH ₃	H	H
	H	H	CN	H
	H	CHO	H	H
	H	H	COOH	H
	H	CH ₂ COOH	H	H
	H	H	CH ₂ COOCH ₃	H
10	H	I	H	H
	H	H	Br	H
	H	H	CONH ₂	H
	H	H	CH ₂ OH	H
	H	COOH	H	H

15


20

Other dihydroxy compounds for use in the preparation of compounds A and B include those of formula II wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table:

25

5

(II)



10

	R	R ₁	R ₂	R ₃	R ₄	R ₅
15	H	H	H	H	H	H
	H	H	Cl	H	H	H
	H	CH ₂ OH	H	H	H	H
	H	H	OH	H	H	H
	H	H	H	CH ₃	H	H
20	H	H	H	CH ₂ Cl	H	H
	H	H	H	COOH	H	H
	H	H	H	CH ₂ COOH	H	H
	H	H	H	CHO	H	H
	H	H	H	H	H	CH ₂ CHO
25	H	H	CONH ₂	H	H ₂	CH ₃
	H	H	H	CN	H	H
	H	H	H	H	CH ₂ COHN ₂	H
	H	H	H	COOCH ₃	H ₃	H
	H	H ₃	OCH ₃	H	H	H

30

Other dihydroxy compounds for use in making compound of formula A and B include those of formula III wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table.

5

10

15




	R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₈	R ₉
20	H	H	H	H	H	H	H	H
	H	H	Cl	H	H	H	H	H
	H	H	H	H	Br	H	H	H
25	H	H	OCH ₃	H	H	H	H	H
	H	H	CONH ₂	H	H	H	H	H
	H	Br	H	H	H	H	H	H
	H	H	H	H	CH ₂ COOH	H	H	H
	H	H	Cl	Cl	H	H	H	H
30	H	CH ₂ COOH	H	H	H	H	H	H
	H	H	CH ₃	H	H	H	H	H
	H	CH ₃	H	H	H	H	H	H
	H	CH ₂ Cl	H	H	H	H	H	H
	H	H	H	I	H	H	H	H
35	H	CH ₂ CN	H	H	H	H	H	H
	H	H	H	H	CH ₂ CH ₂ OH	H	H	H

Additional dihydroxy compounds include those of formula IV wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table.

5

10

(IV)



15

R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉
---	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

20

H	H	H	H	H	H	H	H	H	H
H	H	Cl	H	H	H	Cl	H	H	H
H	H	Cl	Cl	H	H	H	H	H	H
H	H	CONCH ₃	H	H	H	Br	H	H	H
H	H	Br	H	H	H	CON(CH ₃) ₂	H	H	H

25

H	H	H	OCH ₃	H	H	H	H	H	H
H	H	H	H	OCH ₃	H	H	H	H	H
H	H	H	H	CH ₂ COOH	H	H	H	H	H
H	H	COOH	H	H	H	H	H	H	H
H	CH ₃	H	H	H	H	H	H	H	H

30

CH ₃	H	H	H	H	CH ₃	H	H	H	H
H	CH ₂ CH ₃	H	H	H	H	H	Cl	H	H
H	CH ₂ CN	H	H	CH ₂ OH	H	H	H	H	H
H	H	H	I	H	H	H	H	CN	H
H	CH ₂ CH ₂ COOH	H	H	H	H	H	H	H	H

35

H	H	CHO	H	H	H	H	H	H	H
H	H	H	F	H	H	H	H	H	H

Compounds of the following formula are also included:



10 herein R_{15} , R_{16} , R_{17} and R_{18} are independently selected from halogen, alkyl of 1-5 carbons; aryl, acyl of 1-5 carbon hydroxyalkyl of 1-5 carbons and aminoalkyl of 1-5 carbons may be made by reacting the appropriate di, tri or tetrahalotelluride with the appropriate hydroxy compound which may be of the formula: $HO-R_{19}$; wherein R_{19} is alkyl of 1 to 5 carbons, haloalkyl of 1 to 5 carbons, aryl, alkylaryl, 15 alkylamido of 1 to 5 carbons, alkylcarbonyl of 1 to 5 carbons, cyanoalkyl of 1 to 5 carbons, cyanoalkyl of 1 to 5 carbons, and an alkoxyalkyl of 2 to 10 carbons. Specific examples of R_{16} include methyl, ethyl, n-propyl, phenyl, tolyl, amidoethyl, cyanomethyl, methyloxymethyl and 20 CH_2CH_2COOH .

These compounds are described in United States Patent No. 4,761,490 which is incorporated by reference. In addition, $TeCl_4$, $TeBr_4$ and compounds which give in aqueous solution TeO_2 preferably in the form of a complex such as for 25 example TeO_2 complex with citric acid or ethylene glycol.

The preferred compound is ammonium trichloro (dioxoethylene-O,O') tellurate.

30 The topical treatment of warts involves contacting the affected area with a liquid or semisolid composition of the tellurium compound in a liquid or semisolid vehicle. The liquid vehicle may comprise water, dimethyl sulfoxide, propylene glycol, ethanol and solvents containing polyhydroxy groups.

35 The semisolid vehicle may comprise a hydrophilic or a

hydrophobic ointment base such as petrolatum U.S.P., or water washable cream type base such as polyethylene glycol ointment U.S.P.

5 The concentration of the tellurium compound in the topical composition may vary from 1 to 40wt% and more preferably from 15 to 25wt.%. In selected cases where warts are found on cornified epithelial tissue, it may be desirable to coadminister a keratolytic agent such as salicylic acid at concentrations of 20 to 50wt% of the total
10 weight of the tellurium containing composition.

Systemic treatment may be achieved by oral or parenteral administration of the tellurium compound at a dose of 0.1 to 5.0 mg/kg of body weight, preferably 1 to 3mg/kg given daily in divided doses.

15 The preferred method of administration will be determined by the type of wart that is being treated and the location of the wart. The optimum dose and frequency may be determined by the individualized response to the clinical
20 treatment of particular cases.

EXAMPLE 1

25

A human patient with *condyloma acuminatum* in the perianal region is treated with a dispersion of ammonium trichloro (dioxoethylene-O,O') tellurate that is prepared by dissolving
30 a sufficient amount of the tellurate compound in dimethyl sulfoxide to make a 40%w/w solution and then combining that solution with an equal weight of petrolatum, U.S.P. to make a 20%w/w dispersion of the tellurate. This formulation is topically applied twice daily to cover the affected area for
35 a period of about 4 weeks. After a few days the lesion

changes color from pink to grey-black and after about 4 to 5 weeks, the lesion sloughs off without leaving any scarring. Figs. 1-5 show the effect of the therapy on the condyloma at bi-weekly intervals during the period of treatment

5

EXAMPLE 2

A human patient with a verrucca lesion on the hand is treated with the same dispersion of ammonium trichloro (dioxoethylene-O,O') tellurate that was prepared in Example 1. The formulation was applied twice daily for a period of about 4 weeks. After about four weeks the wart sloughs off and leaves no scar on the treated area. Figs. 6-8 show the progress of treatment at biweekly intervals.

15


EXAMPLE 3

A human patient with multiple verrucca lesions on the hand is treated with the same dispersion of ammonium trichloro (dioxoethylene-O,O') tellurate that was prepared in Example 1. The formulation was applied twice daily for a period of about 4 weeks. After about four weeks the wart sloughs off and leaves no scar on the treated area. Figs. 9-11 show the progress of treatment at biweekly intervals.

25


We Claim:

1. A method of treating warts which comprises the
5 administration of a tellurium compound of the formula:



or the complex of $\text{TeO}_2 \cdot \text{HOCH}_2\text{CH}_2 \cdot \text{NH}_4\text{Cl}$;

or



TeO_2 or complexes of TeO_2
(C)

or

PhTeCl_3

(D)

or

TeX₄, when X is Cl, Br or F

or the following complex: TeO₂.HOCH₂CH₂OH.NH₄Cl;

5 or

(C₆H₅)₄P⁺(TeCl₃(O₂C₂H₄))⁻ (E)
wherein t is 1 or 0; u is 1 or 0; v is 1 or 0; R, R₁, R₂, R₃,
R₄, R₅, R₆, R₇, R₈, and R₉ are the same or different and are
independently selected from the group consisting of hydrogen,
10 hydroxyalkyl of 1 to 5 carbons, hydroxy, alkyl or from 1 to 5
carbon atoms, halogen, haloalkyl of 1 to 5 carbon atoms,
carboxy, alkylcarbonylalkyl of 2 to 10 carbons, alkanoyloxy
of 1 to 5 carbon atoms, carboxyalkyl of 1 to 5 carbons atoms,
acyl, amido, cyano, amidoalkyl of 1 to 5 carbons, N-
15 monoalkylamidoalkyl of 2 to 10 carbons, N,N-dialkylamidoalkyl
of 4 to 10 carbons, cyanoalkyl of 1 to 5 carbons alkoxy of 1
to 5 carbon atoms, alkoxyalkyl of 2 to 10 carbon atoms and -
COR₁₀ wherein R₁₀ is alkyl of 1 to 5 carbons; and X is halogen.

20

2. A method as defined in claim 1 wherein the tellurium
compound is ammonium trichloro (dioxoethylene-O,O')
tellurate.

25

3. A method as defined in claim 1 wherein the tellurium
compound is administered topically.

4. A method as defined in claim 1 wherein the tellurium
compound is administered systemically.

30

5. A method as defined in claim 1 wherein the tellurium
compound is administered as a 1 to 30% solution.

6. A method as defined in claim 1 wherein the tellurium
35 compound is administered as a 1 to 30% hydrophilic or

hydrophobic ointment.

5 7. A method as defined in claim 1 wherein the wart is
selected from the group consisting of common warts, flat
warts, genital warts, cutaneous warts, laryngeal papillomas,
and oral papillomas.

10 8. A method as defined in claim 1 wherein the wart is a
common wart.

9. A method as defined in claim 1 wherein the wart is a
genital wart.

15

20

ABSTRACT

5 The subject invention pertains to a method for
treatment of warts which comprises the administration of an
effective amount of a tellurium compound to one who is
afflicted with warts. The method of treatment includes the
topical and systemic administration of a tellurium compound .

10



FIG. 1




FIG. 2



FIG. 3




FIG. 4




FIG. 5



FIG. 8




FIG. 7



FIG. 6



FIG. 9



FIG 10



FIG 11